Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using (111)In-bevacizumab

BACKGROUND: The ability to image vascular endothelial growth factor (VEGF) could enable prospective, non-invasive monitoring of patients receiving anti-angiogenic therapy. This study investigates the specificity and pharmacokinetics of (111)In-bevacizumab binding to VEGF and its use for assessing re...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Neel, Able, Sarah, Allen, Danny, Fokas, Emmanouil, Cornelissen, Bart, Gleeson, Fergus V., Harris, Adrian L., Vallis, Katherine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449352/
https://www.ncbi.nlm.nih.gov/pubmed/28560583
http://dx.doi.org/10.1186/s13550-017-0297-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449352/
https://www.ncbi.nlm.nih.gov/pubmed/28560583
http://dx.doi.org/10.1186/s13550-017-0297-9

Ejemplares similares